What is the share price of Kopran Ltd (KOPRAN) today?
The share price of KOPRAN as on 29th May 2026 is ₹206.27. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Kopran Ltd (KOPRAN) share?
The past returns of Kopran Ltd (KOPRAN) share are- Past 1 week: 23.99%
- Past 1 month: 29.57%
- Past 3 months: 56.47%
- Past 6 months: 46.69%
- Past 1 year: 12.12%
- Past 3 years: 42.95%
- Past 5 years: 10.10%
What are the peers or stocks similar to Kopran Ltd (KOPRAN)?
The peers or stocks similar to Kopran Ltd (KOPRAN) include:What is the market cap of Kopran Ltd (KOPRAN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kopran Ltd (KOPRAN) is ₹995.99 Cr as of 29th May 2026.What is the 52 week high and low of Kopran Ltd (KOPRAN) share?
The 52-week high of Kopran Ltd (KOPRAN) is ₹219 and the 52-week low is ₹107.What is the PE and PB ratio of Kopran Ltd (KOPRAN) stock?
The P/E (price-to-earnings) ratio of Kopran Ltd (KOPRAN) is 38.71. The P/B (price-to-book) ratio is 1.92.Which sector does Kopran Ltd (KOPRAN) belong to?
Kopran Ltd (KOPRAN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Kopran Ltd (KOPRAN) shares?
You can directly buy Kopran Ltd (KOPRAN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Kopran Ltd
KOPRAN Share Price
NSE₹206.276.56% (+12.69)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
KOPRAN Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
KOPRAN Performance & Key Metrics
KOPRAN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 38.72 | 1.92 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.72 | 6.24 | 0.47% |
KOPRAN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
KOPRAN Company Profile
Kopran Limited is engaged in pharmaceutical business. The Company's business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.
SUNPHARMA
PE Ratio
37.61
37.61
1Y Return
5.85%
5.85%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
69.82
69.82
1Y Return
39.53%
39.53%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
29.17
29.17
1Y Return
5.14%
5.14%
Buy Reco %
62.86
62.86
DRREDDY
PE Ratio
25.87
25.87
1Y Return
4.43%
4.43%
Buy Reco %
51.52
51.52
ZYDUSLIFE
PE Ratio
21.52
21.52
1Y Return
16.54%
16.54%
Buy Reco %
53.57
53.57
KOPRAN Sentiment Analysis
KOPRAN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
KOPRAN Stock Summary · March 2025
Kopran Limited is strategically merging with Kopran Laboratories to enhance its foothold in the burgeoning Indian diagnostic market, projected to reach $25 billion by FY '28. This merger, aimed at creating synergies and improving margins through efficient manufacturing of diagnostic kits, reflects management's optimism about future growth, particularly in the healthcare sector. Despite a strong year-over-year revenue increase, the company faces challenges in diversifying its revenue streams, heavily reliant on its clinical chemistry segment. Engaging actively with investors, management has addressed concerns regarding valuation while emphasizing a robust operational strategy focused on B2B opportunities in underserved markets. With plans for significant capital investment and a commitment to service delivery, Kopran is well-positioned to capitalize on the industry's projected growth of 14% to 15%.
KOPRAN Stock Growth Drivers
KOPRAN Stock Growth Drivers
6Merger and Synergies
Kopran Limited is in the process of merging with Kopran Laboratories, aiming to create synergies
Financial Performance and Growth
Kopran Laboratories reported a turnover of approximately INR 68-69 crores for the first nine months,
KOPRAN Stock Challenges
KOPRAN Stock Challenges
3Muted Revenue Performance
The company has reported muted revenue performance for the December period compared to the previous
Seasonality Concerns
There are concerns regarding the seasonality of the company's revenue, as the December period's performance
KOPRAN Forecast
KOPRAN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
KOPRAN
KOPRAN
Income
Balance Sheet
Cash Flow
Quarterly Normal View
KOPRAN Income Statement
KOPRAN Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 161.35 | 195.75 | 142.06 | 152.56 | 166.41 | 175.62 | 137.77 | 117.93 | 194.35 | 234.11 | ||||||||||
Operating & Other expenses | 135.34 | 164.39 | 121.27 | 136.82 | 146.40 | 155.28 | 121.09 | 123.19 | 176.52 | 201.07 | ||||||||||
EBITDA | 26.01 | 31.36 | 20.79 | 15.74 | 20.01 | 20.34 | 16.68 | -5.26 | 17.83 | 33.04 | ||||||||||
| Depreciation/Amortization | 3.27 | 3.59 | 3.87 | 3.85 | 4.00 | 3.87 | 4.26 | 4.28 | 4.42 | 4.52 | ||||||||||
| PBIT | 22.74 | 27.77 | 16.92 | 11.89 | 16.01 | 16.47 | 12.42 | -9.54 | 13.41 | 28.52 | ||||||||||
| Interest & Other Items | 2.24 | 2.59 | 2.18 | 2.23 | 2.16 | 2.77 | 2.54 | 2.09 | 2.67 | 3.17 | ||||||||||
| PBT | 20.50 | 25.18 | 14.74 | 9.66 | 13.85 | 13.70 | 9.88 | -11.63 | 10.74 | 25.35 | ||||||||||
| Taxes & Other Items | 4.72 | 6.55 | 3.64 | 2.26 | 3.46 | 4.03 | 2.44 | -1.70 | 1.40 | 6.48 | ||||||||||
| Net Income | 15.78 | 18.63 | 11.10 | 7.40 | 10.39 | 9.67 | 7.44 | -9.93 | 9.34 | 18.87 | ||||||||||
| EPS | 3.28 | 3.86 | 2.30 | 1.53 | 2.16 | 2.00 | 1.54 | -2.06 | 1.93 | 3.91 |
KOPRAN Company Updates
FY 2026FY 2026
Investor Presentation
May 20PDF
Jan 22PDF
Nov 12PDF
Nov 12PDF
KOPRAN Stock Peers
KOPRAN Past Performance & Peer Comparison
KOPRAN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Kopran Ltd | 38.71 | 1.92 | — |
| Sun Pharmaceutical Industries Ltd | 37.61 | 5.96 | 0.89% |
| Torrent Pharmaceuticals Ltd | 69.82 | 19.67 | — |
| Cipla Ltd | 29.17 | 3.62 | 0.93% |
KOPRAN Stock Price Comparison
Compare KOPRAN with any stock or ETFCompare KOPRAN with any stock or ETF
KOPRAN
KOPRAN Holdings
KOPRAN Shareholdings
KOPRAN Promoter Holdings Trend
KOPRAN Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
KOPRAN Institutional Holdings Trend
KOPRAN Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.30%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
KOPRAN Shareholding Pattern
KOPRAN Shareholding Pattern
KOPRAN Shareholding History
KOPRAN Shareholding History
Foreign Institutions
Mutual Funds Invested in KOPRAN
Mutual Funds Invested in KOPRAN
No mutual funds holding trends are available
Top 1 Mutual Funds holding Kopran Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0005% | Percentage of the fund’s portfolio invested in the stock 0.03% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 112/130 (-3) |
Compare 3-month MF holding change on Screener
smallcases containing KOPRAN stock
smallcases containing KOPRAN stock
Looks like this stock is not in any smallcase yet.
KOPRAN Events
KOPRAN Events
KOPRAN Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
KOPRAN Dividend Trend
No dividend trend available
KOPRAN Upcoming Dividends
KOPRAN Upcoming Dividends
No upcoming dividends are available
KOPRAN Past Dividends
KOPRAN Past Dividends
Cash Dividend
Ex DateEx DateSep 4, 2025
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 4, 2025
Cash Dividend
Ex DateEx DateSep 2, 2024
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 2, 2024
Cash Dividend
Ex DateEx DateSep 7, 2023
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 7, 2023
Cash Dividend
Ex DateEx DateAug 4, 2022
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Aug 4, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Aug 5, 2021
KOPRAN Stock News & Opinions
KOPRAN Stock News & Opinions
Articles & Videos
Earnings
Earnings
Kopran consolidated net profit rises 94.94% in the March 2026 quarterNet profit of Kopran rose 94.94% to Rs 18.87 crore in the quarter ended March 2026 as against Rs 9.68 crore during the previous quarter ended March 2025. Sales rose 35.77% to Rs 234.02 crore in the quarter ended March 2026 as against Rs 172.36 crore during the previous quarter ended March 2025. For the full year,net profit declined 33.26% to Rs 25.73 crore in the year ended March 2026 as against Rs 38.55 crore during the previous year ended March 2025. Sales rose 8.23% to Rs 681.42 crore in the year ended March 2026 as against Rs 629.60 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales234.02172.36 36 681.42629.60 8 OPM %14.089.92 -9.0911.58 - PBDT29.8617.58 70 51.8367.54 -23 PBT25.3513.71 85 34.3651.95 -34 NP18.879.68 95 25.7338.55 -33 Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Corporate
Board of Kopran recommends final dividendKopran announced that the Board of Directors of the Company at its meeting held on 19 May 2026, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.
1 week agoCapital Market - Live
Corporate
Corporate
Kopran to announce Quarterly ResultKopran will hold a meeting of the Board of Directors of the Company on 19 May 2026.
3 weeks agoCapital Market - Live
Corporate
Corporate
Kopran schedules EGMKopran announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 3 June 2026.
4 weeks agoCapital Market - Live
Corporate
Corporate
Kopran to hold board meetingKopran will hold a meeting of the Board of Directors of the Company on 22 January 2026.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Earnings
Kopran reports consolidated net loss of Rs 9.92 crore in the September 2025 quarterNet loss of Kopran reported to Rs 9.92 crore in the quarter ended September 2025 as against net profit of Rs 7.38 crore during the previous quarter ended September 2024. Sales declined 22.20% to Rs 117.91 crore in the quarter ended September 2025 as against Rs 151.56 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales117.91151.56 -22 OPM %-4.489.72 - PBDT-7.3413.50 PL PBT-11.639.64 PL NP-9.927.38 PL Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Kopran to conduct board meetingKopran will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
Spotlight
Kopran Ltd Spurts 4.13%Kopran Ltd gained 4.13% today to trade at Rs 163.7. The BSE Healthcare index is up 0.34% to quote at 44693.47. The index is down 0.96 % over last one month. Among the other constituents of the index, Aarti Pharmalabs Ltd increased 2.6% and Rainbow Childrens Medicare Ltd added 1.58% on the day. The BSE Healthcare index went up 7.92 % over last one year compared to the 1.11% surge in benchmark SENSEX. Kopran Ltd has lost 8.09% over last one month compared to 0.96% fall in BSE Healthcare index and 0.54% drop in the SENSEX. On the BSE, 25 shares were traded in the counter so far compared with average daily volumes of 20242 shares in the past one month. The stock hit a record high of Rs 369.2 on 09 Sep 2024. The stock hit a 52-week low of Rs 156.5 on 08 Aug 2025.Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Corporate
Kopran to hold AGMKopran announced that the 66th Annual General Meeting(AGM) of the company will be held on 11 September 2025.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Earnings
Kopran consolidated net profit declines 32.88% in the June 2025 quarterNet profit of Kopran declined 32.88% to Rs 7.45 crore in the quarter ended June 2025 as against Rs 11.10 crore during the previous quarter ended June 2024. Sales declined 3.03% to Rs 135.22 crore in the quarter ended June 2025 as against Rs 139.44 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales135.22139.44 -3 OPM %10.4513.02 - PBDT14.1518.61 -24 PBT9.8914.73 -33 NP7.4511.10 -33 Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 11.96%, vs industry avg of 9.86%
Over the last 5 years, market share increased from 0.14% to 0.15%
Over the last 5 years, net income has grown at a yearly rate of 12.91%, vs industry avg of 19.71%